Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Denali Therapeutics has raised $200.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in December 2025.
Denali Therapeutics's investors include ARCH Venture Partners, Google Ventures, Baillie Gifford, Flagship Pioneering, F-Prime.
Denali Therapeutics is headquartered in San Francisco, United States.
Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Denali Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Denali Therapeutics — Funding & Investors." VCBacked, December 4, 2025, https://www.vcbacked.co/company/denali-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Denali Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/denali-therapeutics
{{cite web |title=Denali Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/denali-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated